Last reviewed · How we verify
AZD9833 with everolimus
mTOR inhibitor
mTOR inhibitor Used for Breast cancer.
At a glance
| Generic name | AZD9833 with everolimus |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | SERD |
| Target | mTOR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
AZD9833 is a selective estrogen receptor degrader (SERD) in combination with everolimus, an mTOR inhibitor, which targets the mTOR pathway to inhibit cell growth and proliferation.
Approved indications
- Breast cancer
Common side effects
- Stomatitis
- Fatigue
- Nausea
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD9833 with everolimus CI brief — competitive landscape report
- AZD9833 with everolimus updates RSS · CI watch RSS
- AstraZeneca portfolio CI